









Markets
/
Stocks
/
nasdaq-zts
/

Zoetis Inc

ZTS

121.169USD

-0.551-0.45%

Market hours （ET）Quotes delayed by 15 min

53.49BMarket Cap

20.40P/E TTM



Zoetis Inc

121.169

-0.551-0.45%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Zoetis Inc

Currency: USD Updated: 2026-01-29

Key Insights

Zoetis Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 46 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 156.63.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Zoetis Inc's Score

Industry at a Glance

Industry Ranking

46 / 159

Overall Ranking

128 / 4540

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Zoetis Inc Highlights

StrengthsRisks

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 9.26B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 32.66%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 32.66%.

Undervalued

The company’s latest PE is 20.49, at a low 3-year percentile range.

Held by Mairs and Power

Star Investor Mairs and Power holds 7.22K shares of this stock.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

156.628

Target Price

+25.34%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-29

The current financial score of Zoetis Inc is 8.99, ranking 22 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.40B, representing a year-over-year increase of 0.50%, while its net profit experienced a year-over-year increase of 5.72%.

Score

Industry at a Glance

Previous score

8.99

Change



Financials

6.88

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.37

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Zoetis Inc's Company Valuation

Currency: USD Updated: 2026-01-29

The current valuation score of Zoetis Inc is 5.60, ranking 145 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 20.49, which is 104.71% below the recent high of 41.95 and 4.90% above the recent low of 19.49.

Score

Industry at a Glance

Previous score

5.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 46/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-29

The current earnings forecast score of Zoetis Inc is 7.80, ranking 96 out of 159 in the Pharmaceuticals industry. The average price target is 165.00, with a high of 200.00 and a low of 130.00.

Score

Industry at a Glance

Previous score

7.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

156.628

Target Price

+25.34%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Zoetis Inc

ZTS

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-29

The current price momentum score of Zoetis Inc is 5.96, ranking 135 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 128.15 and the support level at 118.27, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.98

Change

-0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.834

Sell

RSI(14)

40.715

Neutral

STOCH(KDJ)(9,3,3)

19.590

Sell

ATR(14)

2.718

High Vlolatility

CCI(14)

-177.898

Sell

Williams %R

93.382

Oversold

TRIX(12,20)

-0.013

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

123.316

Sell

MA10

123.923

Sell

MA20

125.258

Sell

MA50

123.365

Sell

MA100

132.136

Sell

MA200

144.260

Sell

Institutional Confidence

Currency: USD Updated: 2026-01-29

The current institutional shareholding score of Zoetis Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 99.51%, representing a quarter-over-quarter increase of 0.32%. The largest institutional shareholder is The Vanguard, holding a total of 47.78M shares, representing 10.84% of shares outstanding, with 16.70% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

47.78M

+13.48%

BlackRock Institutional Trust Company, N.A.

22.80M

+0.64%

State Street Investment Management (US)

19.65M

-0.46%

State Farm Insurance Companies

16.87M

+0.13%

Geode Capital Management, L.L.C.

11.14M

+0.52%

Wellington Management Company, LLP

8.54M

-3.92%

Polen Capital Management, LLC

7.52M

-10.74%

Morgan Stanley Investment Management Ltd. (UK)

7.48M

+10.69%

Wells Fargo Advisors

5.64M

-3.32%

Norges Bank Investment Management (NBIM)

5.19M

+2.60%

Risk Assessment

Currency: USD Updated: 2026-01-29

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Zoetis Inc is 7.34, ranking 37 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Zoetis Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.